HIV care and treatment programs continue to evolve in response to shifting clinical guidelines, new evidence-based practices, changes in domestic and donor funding, emerging technologies, and environmental pressures. Since 2009, the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium has periodically surveyed participating clinics to document clinic characteristics and the availability of HIV-related services. These prior surveys provide essential context for interpreting variations and trends in HIV care outcomes. The 2026 IeDEA site assessment, launched in August 2026, is a cross-sectional descriptive study intended to update that programmatic and service delivery profile across diverse global settings.
The 2026 site assessment is designed to capture HIV-related services and practices at IeDEA-affiliated care and treatment sites across 42 countries. A total of 232 eligible clinics were identified to receive survey materials. Survey instruments and links to an online REDCap questionnaire were distributed to these clinics in September 2026, with a stated deadline for completion of November 30, 2026.
The study is cross-sectional and descriptive. It relies on self-administration of the questionnaire by clinic staff and aims to document the availability and real-world uptake of service delivery approaches relevant to people living with or at risk of HIV.
The survey questionnaire was developed through two complementary processes. First, investigators reviewed questions and data elements used in prior IeDEA consortium-wide surveys to ensure continuity and comparability with past assessments. Second, an open call to IeDEA investigators solicited new survey content to address emerging implementation science priorities and timely questions for the global HIV community.
The resulting instrument is intended for self-administration by clinic personnel and is deployed as an online REDCap form. The protocol paper describes these development steps and distribution plans but does not report responses or results, as the document is a protocol for the assessment.
Planned analyses of the cross-sectional data will address multiple service delivery and implementation topics. The protocol lists the following focal areas for examination:
HIV care delivery in the context of funding constraints and changing financing landscapes.
Roll-out and implementation of differentiated service delivery models designed to tailor care intensity and modalities to patient needs.
Availability and provision of pre-exposure prophylaxis (PrEP) for people at risk of HIV.
Adoption of long-acting injectable antiretroviral therapy (ART) where available.
Prevention, screening, and treatment services for comorbid conditions among people living with HIV (PLHIV), including viral hepatitis, mental health and substance use disorders, cardiovascular disease, and cancers.
Integration of HIV care with other health services to support comprehensive care.
Clinic-level vulnerability to extreme weather events and related service disruptions.
The study is descriptive in nature; the protocol specifies topics and analytic priorities but does not provide outcome data in this pre-results document.
A determination of "non-human subjects" research was made by the Vanderbilt University Medical Center Human Research Protections Program for this protocol. The protocol states that survey findings will be shared with local partners and stakeholders across IeDEA, presented at regional and global conferences, and submitted for publication in peer-reviewed journals.
The authors indicate that all data produced in the study will be available upon reasonable request. As this document is a protocol, no primary survey data or analytic results are reported here.
The protocol lists funding from multiple institutes within the U.S. National Institutes of Health, as declared in the source. The authors declared no competing interests. The copyright holder has granted medRxiv a license to display the preprint under a CC-BY-NC 4.0 International license.
This article is a protocol describing the 2026 IeDEA site assessment methods, instrument development, sampling frame, planned analyses, and dissemination plans. It does not present survey responses or analytic findings. Any details beyond those reported in the protocol (for example, response rates, specific clinic-level results, or inferred impacts of programmatic changes) were not reported in the source and therefore are not included here.